The Motley Fool
21 Jun 2026, 22:05 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Grail's Galleri MCED test missed the primary endpoint of demonstrating a statistically significant reduction in Stage III-IV cancers in its NHS-Galleri trial. — Missing a primary endpoint in a landmark trial is a major fundamental setback that typically reduces the probability of regulatory approval and market adoption.
-0.80Grail is currently engaged in an iterative process with the FDA to secure approval for the Galleri test despite the missed trial endpoint. — Continued engagement with the FDA suggests a path to approval still exists, providing a potential catalyst for a stock recovery.
+0.40Management believes upcoming 12-month follow-up data from the NHS trial may eventually prove the test's efficacy as more cancers emerge in the control group. — Positive follow-up data would mitigate the impact of the initial miss and improve the prospects for insurance coverage.
+0.30Continue reading
6 related stories
Search tags
The NHS trial showed a favorable trend toward fewer Stage III-IV cancers specifically within a pre-specified group of 12 deadly cancers. — Success in a high-severity subset of cancers provides a partial proof-of-concept that could support a narrower regulatory label.
+0.20Which stocks this story touches
The company missed a primary endpoint in a landmark trial and seen significant stock decline, despite some recovery and potential for future FDA approval.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Seeking Alpha
10h ago
